新辅助临床试验为癌症药物发现提供了一个机会之窗。
Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery.
机构信息
The neoAdjuvant Research Group to Evaluate Therapeutics (TARGET), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Immunotherapy and Novel TargEt Research Across Clinical Teams (INTERACT), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
出版信息
Nat Med. 2022 Apr;28(4):626-629. doi: 10.1038/s41591-022-01681-x.
Abstract
Window-of-opportunity trials, during which patients receive short-duration pre-surgical therapies, provide a platform for understanding the therapies’ mechanisms of action, but will require a paradigm shift in trial design, specimen collection and analysis.
摘要
机会之窗试验，在此期间患者接受短疗程术前治疗，为了解治疗的作用机制提供了一个平台，但需要在试验设计、标本采集和分析方面进行范式转变。
相似文献
1
Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery.新辅助临床试验为癌症药物发现提供了一个机会之窗。
Nat Med. 2022 Apr;28(4):626-629. doi: 10.1038/s41591-022-01681-x.
2
Drug development: neoadjuvant opportunities in breast cancer.药物研发：乳腺癌的新辅助治疗机遇
Am Soc Clin Oncol Educ Book. 2013:73-9. doi: 10.14694/EdBook_AM.2013.33.73.
3
Cracking open window of opportunity trials.开启机会性试验之窗。
J Clin Oncol. 2012 Jul 20;30(21):2573-5. doi: 10.1200/JCO.2012.42.3293. Epub 2012 May 7.
4
Neoadjuvant breast cancer therapy and drug development.新辅助乳腺癌治疗与药物研发。
Clin Adv Hematol Oncol. 2015 Nov;13(11):755-61.
5
Neoadjuvant trials could speed up drug approvals.新辅助试验可以加快药物审批。
J Natl Cancer Inst. 2014 Mar;106(3):dju072. doi: 10.1093/jnci/dju072. Epub 2014 Mar 7.
6
Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.HER2阳性乳腺癌新辅助治疗的长期结局
Clin Adv Hematol Oncol. 2016 Jul;14(7):520-30.
7
Preoperative chemotherapy for breast cancer.乳腺癌的术前化疗。
Clin Adv Hematol Oncol. 2004 Apr;2(4):212, 215.
8
Neoadjuvant Trials in ER Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.雌激素受体阳性乳腺癌的新辅助试验：加速药物研发与发现的工具
Cancer Discov. 2017 Jun;7(6):561-574. doi: 10.1158/2159-8290.CD-17-0228. Epub 2017 May 11.
9
Neoadjuvant endocrine therapy and window of opportunity trials: new standards in the treatment of breast cancer?新辅助内分泌治疗与机会窗试验：乳腺癌治疗的新标准？
Minerva Chir. 2015 Jun;70(3):181-93. Epub 2015 Mar 4.
10
Chemotherapy: Neoadjuvant trial design: time for a brave new world?化疗：新辅助试验设计：勇敢新世界的时刻到了？
Nat Rev Clin Oncol. 2010 Jul;7(7):359-60. doi: 10.1038/nrclinonc.2010.85.
引用本文的文献
1
Improving outcomes of patients with pancreatic cancer.改善胰腺癌患者的治疗效果。
Nat Rev Clin Oncol. 2025 May 6. doi: 10.1038/s41571-025-01019-9.
2
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response.新辅助免疫疗法治疗错配修复缺陷型和微卫星稳定型结直肠癌：治疗策略和可能的反应生物标志物。
Nat Rev Clin Oncol. 2024 Dec;21(12):839-851. doi: 10.1038/s41571-024-00943-6. Epub 2024 Sep 24.
3
Multiplexed immunohistochemical analysis of the immune microenvironment of biliary tract cancers pre- & post-neoadjuvant chemotherapy: case series.新辅助化疗前后胆道癌免疫微环境的多重免疫组化分析：病例系列
Ann Transl Med. 2024 Aug 1;12(4):78. doi: 10.21037/atm-23-1928. Epub 2024 Jun 5.
4
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours.定义实体瘤中免疫检查点抑制剂的临床有用生物标志物。
Nat Rev Cancer. 2024 Jul;24(7):498-512. doi: 10.1038/s41568-024-00705-7. Epub 2024 Jun 12.
5
Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment.新辅助治疗后转移性乳腺癌的机器学习和机制建模。
PLoS Comput Biol. 2024 May 3;20(5):e1012088. doi: 10.1371/journal.pcbi.1012088. eCollection 2024 May.
6
Embracing cancer complexity: Hallmarks of systemic disease.拥抱癌症的复杂性：全身性疾病的特征。
Cell. 2024 Mar 28;187(7):1589-1616. doi: 10.1016/j.cell.2024.02.009.
7
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.辅助和新辅助免疫疗法在肝细胞癌中的应用。
Nat Rev Clin Oncol. 2024 Apr;21(4):294-311. doi: 10.1038/s41571-024-00868-0. Epub 2024 Feb 29.
8
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer.贝伐珠单抗联合巴替利单抗在局部晚期错配修复功能正常结直肠癌中的疗效模式。
Oncogene. 2023 Oct;42(44):3252-3259. doi: 10.1038/s41388-023-02835-y. Epub 2023 Sep 21.
9
Spatial predictors of immunotherapy response in triple-negative breast cancer.三阴性乳腺癌免疫治疗反应的空间预测因子。
Nature. 2023 Sep;621(7980):868-876. doi: 10.1038/s41586-023-06498-3. Epub 2023 Sep 6.
10
The complementarity of DDR, nucleic acids and anti-tumour immunity.DDR、核酸和抗肿瘤免疫的互补性。
Nature. 2023 Jul;619(7970):475-486. doi: 10.1038/s41586-023-06069-6. Epub 2023 Jul 19.
Zotero 插件